section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Derm: rash ( in patients with cystic fibrosis), ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, urticaria.

GI: diarrhea, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), constipation, drug-induced hepatitis, nausea, vomiting.

GU: interstitial nephritis, renal failure.

Hemat: bleeding, leukopenia, neutropenia, thrombocytopenia.

Local: pain, phlebitis at IV site.

Neuro: confusion, dizziness, headache, insomnia, lethargy, SEIZURES (HIGHER DOSES).
Misc: fever ( in cystic fibrosis patients), hemophagocytic lymphohistiocytosis, (INCLUDING ANAPHYLAXIS AND SERUM SICKNESS)HYPERSENSITIVITY REACTIONS , superinfection.

Interactions

Drug-Drug:

Availability

(Generic available)

Route/Dosage

Contains 2.84 mEq (65 mg) sodium/g of piperacillin; adult doses below expressed as combined piperacillin/tazobactam content

Appendicitis/Peritonitis

Renal Impairment

Nosocomial Pneumonia

Renal Impairment

Skin and Skin Structure Infections, Gynecologic Infections, and Community-Acquired Pneumonia

Renal Impairment

US Brand Names

Zosyn

Action

Therapeutic Effects:

Spectrum:

Classifications

Therapeutic Classification: anti-infectives

Pharmacologic Classification: extended spectrum penicillins

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Widely distributed. Enters CSF well only when meninges are inflamed.

Metabolism/Excretion: Piperacillin (68%) and tazobactam (80%) are mostly excreted unchanged by the kidneys.

Half-life: Adults: 0.7–1.2 hr; Children (6 mo–12 yr): 0.7–0.9 hr; Infants (2–5 mo): 1.4 hr.

Time/Action Profile

(piperacillin plasma concentrations)

ROUTEONSETPEAKDURATION
IVrapidend of infusion4–6 hr

Patient/Family Teaching

Pronunciation

pi-PER-a-sill-in/tay-zoe-BAK-tam